press release
Feb. 16, 2010, 7:00 a.m. EST =C2=B7
NanoViricides Announces a Research Agreement With Leading Dengue = Virus=20 Researcher at the University of California, Berkeley
WEST HAVEN, Conn., Feb 16, 2010 (BUSINESS WIRE) -- NanoViricides, = Inc. (OTC=20 BB: NNVC.OB) (the "Company"), reports that it has signed a research and=20 development agreement with Dr. Eva Harris's laboratory at the University = of=20 California, Berkeley (UC Berkeley).
Under this agreement, Dr. Harris and coworkers will evaluate the=20 effectiveness of nanoviricides(R) drug candidates against various dengue = viruses. Cell culture models as well as in vivo animal studies will be = employed=20 for testing the drug candidates.
The Company believes that a nanoviricide drug under development can = be=20 expected to be a broad-spectrum anti-dengue antiviral treatment capable = of=20 attacking all four dengue virus serotypes and their variant strains. = Currently=20 there are no approved vaccines for the prevention of dengue, nor drugs = for=20 treatment of dengue virus infection. The worldwide market size for an = effective=20 anti-dengue treatment may be as large as that for Hepatitis C virus = treatment,=20 or in the billions of dollars, based on current population exposure = data.
Dr. Eva Harris is a Professor of Infectious Diseases at UC Berkeley. = She is a=20 leading researcher in the field of dengue. Her group has developed a = unique=20 animal model for dengue virus infection and disease that effectively = emulates=20 the pathology seen in humans. In particular, the critical problem of = dengue=20 virus infection, called "Antibody-Dependent Enhancement" (ADE), is = reproduced in=20 this animal model. When a person who was previously infected with one = serotype=20 of dengue virus is later infected by a different serotype, the = antibodies=20 produced by the immune system can lead to increased severity of the = second=20 dengue infection, instead of controlling it. ADE thus can lead to severe = dengue=20 disease or dengue hemorrhagic fever (DHF).
Dengue and dengue hemorrhagic fever/dengue shock syndrome are =
emerging as=20
serious global health problems. Dengue is endemic in large parts of the =
world.=20
It now threatens over 3 billion people world-wide or 40% of world =
population,=20
and is considered a re-emerging threat in the United States. Dengue is=20
officially considered a "neglected tropical disease" by the World Health =
Organization. About 50-100 million people are infected by dengue virus =
every=20
year. In fact, just recently, the government of Cali, Columbia declared =
a dengue=20
emergency because of the number of dengue infections and deaths. =
Globalization=20
and warming climates along with changes in the ecology of the =
virus-carrying=20
mosquito are accelerating the spread of the virus. Without proper =
treatment, DHF=20
fatality rates can exceed 20%. (Source: WHO Dengue and dengue =
hemorrhagic fever=20
Fact Sheet No. 117, March 2009;
Using computer modeling, the Company has developed a library of small = chemical ligands that bind to dengue virus envelope proteins. Using = these=20 ligands, a number of candidate nanoviricides that are capable of = attacking the=20 dengue virus have been developed. The Company believes that these = nanoviricide=20 drug candidates mimic the natural, common attachment function by which = the four=20 different dengue virus serotypes bind to the body's host cells.
"We are very excited about this association with the Harris Lab," = said Dr.=20 Eugene Seymour, MD, MPH, CEO of the Company, adding, "We will now be = able to=20 rapidly advance our anti-dengue therapeutics program."
About the Dr. Eva Harris' Laboratory at the University of California, = Berkeley
The Harris Laboratory in the Division of Infectious Diseases in the = School of=20 Public Health at the University of California, Berkeley has developed a=20 multidisciplinary approach to study the molecular virology, = pathogenesis, and=20 epidemiology of dengue, the most prevalent mosquito-borne viral disease = in=20 humans. Their work addresses viral and host factors that modulate = disease=20 severity. One major research focus has been the development of a mouse = model to=20 study viral tropism and pathogenesis, investigate the immune response to = dengue=20 virus infection, and evaluate candidate anti-viral therapeutics. Dr. = Harris'=20 field work focuses on laboratory-based and epidemiological studies of = dengue in=20 endemic Latin American countries, particularly in Nicaragua, where = ongoing=20 projects include clinical and biological studies of severe dengue, a = pediatric=20 cohort study of dengue and influenza transmission in Managua, and a = project on=20 evidence-based, community-derived interventions for prevention of dengue = via=20 control of its mosquito vector.
About NanoViricides:
NanoViricides, Inc. (
This press release contains forward-looking statements that reflect = the=20 Company's current expectation regarding future events. Actual events = could=20 differ materially and substantially from those projected herein and = depend on a=20 number of factors. Certain statements in this release, and other written = or oral=20 statements made by NanoViricides, Inc. are "forward-looking statements" = within=20 the meaning of Section 27A of the Securities Act of 1933 and Section 21E = of the=20 Securities Exchange Act of 1934. You should not place undue reliance on=20 forward-looking statements since they involve known and unknown risks,=20 uncertainties and other factors which are, in some cases, beyond the = Company's=20 control and which could, and likely will, materially affect actual = results,=20 levels of activity, performance or achievements. The Company assumes no=20 obligation to publicly update or revise these forward-looking statements = for any=20 reason, or to update the reasons actual results could differ materially = from=20 those anticipated in these forward-looking statements, even if new = information=20 becomes available in the future. Important factors that could cause = actual=20 results to differ materially from the company's expectations include, = but are=20 not limited to, those factors that are disclosed under the heading "Risk = Factors" and elsewhere in documents filed by the company from time to = time with=20 the United States Securities and Exchange Commission and other = regulatory=20 authorities. Although it is not possible to predict or identify all such = factors, they may include the following: demonstration and proof of = principle in=20 pre-clinical trials that a nanoviricide is safe and effective; = successful=20 development of our product candidates; our ability to seek and obtain = regulatory=20 approvals, including with respect to the indications we are seeking; the = successful commercialization of our product candidates; and market = acceptance of=20 our products.
SOURCE: NanoViricides, Inc.
NanoViricides, Inc.=20 Amanda Schuon, 310-550-7200=20 info@nanoviricides.com
Copyright Business Wire 2010
![3DComtex](3D"http://i.mktw.net/images/comtexsmall.jpg")
=20
Most Popular
Partner=20
Center =C2=BB
Featured Stories
-
SINGAPORE (MarketWatch) -- Asian shares = were higher=20 Wednesday with a rise in commodities and metals prices... =
-
Beverage sales suffer an anemic start to = the year=20 as overall demand continues to decline, though...
-
=20
-
Will the Bank of Japan say anything about = a price=20 target, after Japan's finance minister says the...
-
Lack of insurance or timely access to = your regular=20 doctor doesn=E2=80=99t have to mean going without needed health...=20
6:22 AM EST
February 17, 2010
/marketstate/country/us=20
New York
Closed
London
Open
Tokyo
Closed
Latest = News
- /news/latest
BOE voted 9-0 to pause bond purchases
- Loading more headlines...
Kiosk
-
12410496000001272585600000
Commodities Corner
Myra = P.=20 Saefong
Knock=20 on wood
It=E2=80=99s tough to justify lumber=E2=80=99s = climb to its highest=20 price level in more than two years as built on solid ground. But there = may be=20 underlying reasons. -
12410496000001241049600000
Community
-
12427344000001274270400000
Commentary
![3D""=20](3D"http://i.mktw.net/_newsimages/columnists/kiosk/friedman-jon.png")
Jon FRIEDMAN'S MEDIA = WEB
Now that we=E2=80=99ve squared away the = fates of Jay Leno=20 and Conan O=E2=80=99Brien, it=E2=80=99s time for us all to speculate = about Katie Couric=E2=80=99s=20 future, writes Jon Friedman. -
12389328000001270468800000
Diary of a Recession Baby
Child-care=20 dilemma
Taking care of children is tricky when both parents = work, but=20 when one parent gets sick, balancing work and child care can be = downright=20 daunting. -
12410496000001241049600000
TaxWatch
Double=20 whammy
Losing a job is stressful enough. But then come the=20 unexpected income-tax costs of unemployment insurance. -
12518208000001251820800000
The Winter Olympics
Ready=20 for some curling?
Some say "shuffleboard on ice" is just a = game. but=20 Bill Mann notes Canucks are crazy about the sport. -
12548808000001254880800000
Personal Finance Minute
Nothing= =20 stealthy![3D""=20](3D"http://i.mktw.net/_newsimages/icon/video/video-kiosk.png")
April 15 is coming up fast, so watch for an estate-tax = pitfall=20 and consider a deductible donation for Haiti relief, Andrea Coombes=20 reports.
![3Dlogo=20](3D"http://i.mktw.net/MW5/content/images/foot-wsjdn-logo.png"){kind=logo}
=20
![3Dlogo=20](3D"http://i.mktw.net/MW5/content/images/foot-mw-logo.png"){kind=logo}
Copyrig=
ht =C2=A9 2010=20
MarketWatch, Inc. All rights reserved.
By using this site, you agree =
to the=20
Terms of =
Service=20
and Privacy =
Policy.=20
Intraday data provided by
The action you requested requires a MarketWatch Community display=20 name.
Sign In
Community
Get=20 your FREE membership now =C2=BB
MarketWatch Community is a free service that lets you discover, = organize and=20 share MarketWatch stories with other readers.
The action you requested is only available to MarketWatch =
members.
Please=20
sign in or register.
Sign In
Register
Don't have a MarketWatch = account?
By registering, you are agreeing to MarketWatch's Terms of Service = and to=20 receiving periodic news and special offers via email about MarketWatch=20 enhancements, products and services.
![](3D"http://s0.2mdn.net/2457383/Button_Peter_170x40.gif") |
![](3D"http://s0.2mdn.net/1183784/1x1.GIF"){kind=spacer} |
Trade Now at Fidelity |
![](3D"http://s0.2mdn.net/1183784/1x1.GIF"=20){kind=spacer} |
","
"]||[0,"",""];div.innerHTML=3Dwrap[1]+elem+wrap[2]=
;while(wrap[0]--)
div=3Ddiv.lastChild;if(!jQuery.support.tbody){var =
hasBody=3D/"&&!hasBod=
y?div.childNodes:[];for(var j=3Dtbody.length-1;j>=3D0;--j)
if(jQuery.nodeName(tbody[j],"tbody")&&!tbody[j].childNodes.length)
tbody[j].parentNode.removeChild(tbody[j]);}
if(!jQuery.support.leadingWhitespace&&/^\s/.test(elem))
div.insertBefore(context.createTextNode(elem.match(/^\s*/)[0]),div.firstC=
hild);elem=3DjQuery.makeArray(div.childNodes);}
if(elem.nodeType)
ret.push(elem);else
ret=3DjQuery.merge(ret,elem);});if(fragment){for(var =
i=3D0;ret[i];i++){if(jQuery.nodeName(ret[i],"script")&&(!ret[i].type||ret=
[i].type.toLowerCase()=3D=3D=3D"text/javascript")){scripts.push(ret[i].pa=
rentNode?ret[i].parentNode.removeChild(ret[i]):ret[i]);}else{if(ret[i].no=
deType=3D=3D=3D1)
ret.splice.apply(ret,[i+1,0].concat(jQuery.makeArray(ret[i].getElementsBy=
TagName("script"))));fragment.appendChild(ret[i]);}}
return scripts;}
return =
ret;},attr:function(elem,name,value){if(!elem||elem.nodeType=3D=3D3||elem=
.nodeType=3D=3D8)
return undefined;var =
notxml=3D!jQuery.isXMLDoc(elem),set=3Dvalue!=3D=3Dundefined;name=3Dnotxml=
&&jQuery.props[name]||name;if(elem.tagName){var =
special=3D/href|src|style/.test(name);if(name=3D=3D"selected"&&elem.paren=
tNode)
elem.parentNode.selectedIndex;if(name in =
elem&¬xml&&!special){if(set){if(name=3D=3D"type"&&jQuery.nodeName(elem=
,"input")&&elem.parentNode)
throw"type property can't be changed";elem[name]=3Dvalue;}
if(jQuery.nodeName(elem,"form")&&elem.getAttributeNode(name))
return =
elem.getAttributeNode(name).nodeValue;if(name=3D=3D"tabIndex"){var =
attributeNode=3Delem.getAttributeNode("tabIndex");return =
attributeNode&&attributeNode.specified?attributeNode.value:elem.nodeName.=
match(/(button|input|object|select|textarea)/i)?0:elem.nodeName.match(/^(=
a|area)$/i)&&elem.href?0:undefined;}
return elem[name];}
if(!jQuery.support.style&¬xml&&name=3D=3D"style")
return jQuery.attr(elem.style,"cssText",value);if(set)
elem.setAttribute(name,""+value);var =
attr=3D!jQuery.support.hrefNormalized&¬xml&&special?elem.getAttribute(=
name,2):elem.getAttribute(name);return =
attr=3D=3D=3Dnull?undefined:attr;}
if(!jQuery.support.opacity&&name=3D=3D"opacity"){if(set){elem.zoom=3D1;el=
em.filter=3D(elem.filter||"").replace(/alpha\([^)]*\)/,"")+
(parseInt(value)+''=3D=3D"NaN"?"":"alpha(opacity=3D"+value*100+")");}
return =
elem.filter&&elem.filter.indexOf("opacity=3D")>=3D0?(parseFloat(elem.filt=
er.match(/opacity=3D([^)]*)/)[1])/100)+'':"";}
name=3Dname.replace(/-([a-z])/ig,function(all,letter){return =
letter.toUpperCase();});if(set)
elem[name]=3Dvalue;return =
elem[name];},trim:function(text){return(text||"").replace(/^\s+|\s+$/g,""=
);},makeArray:function(array){var ret=3D[];if(array!=3Dnull){var =
i=3Darray.length;if(i=3D=3Dnull||typeof =
array=3D=3D=3D"string"||jQuery.isFunction(array)||array.setInterval)
ret[0]=3Darray;else
while(i)
ret[--i]=3Darray[i];}
return ret;},inArray:function(elem,array){for(var =
i=3D0,length=3Darray.length;iOne or more of the symbols you =
have chosen does not contain trade data for this time frame. Please =
choose a longer timeframe.
";}
var =
ctx=3Dthis.drawingContext;if(ctx!=3Dnull){ctx.clearRect(0,0,this.width,th=
is.height);this._clearLabels();target.append(errorMessage);}
return;}
var data=3Dthis.data.Data;if(data.length>1){var =
tradesExist=3Dfalse;for(var i=3D0;iOne or more of the symbols you have chosen does not =
contain trade data for this time frame. Please choose a longer =
timeframe.
";var =
ctx=3Dthis.drawingContext;if(ctx!=3Dnull){ctx.clearRect(0,0,this.width,th=
is.height);this._clearLabels();target.append(errorMessage);}
return;}}
this._barFactor=3Dthis.data.BarFactor;this._barSize=3Dthis.data.BarSize;t=
his._chartUnit=3Dthis.data.xAxisLabelInfo.chartUnit;this._displayUnit=3Dt=
his.data.xAxisLabelInfo.displayUnit;this._timeLines=3Dthis.data.xAxisLabe=
lsObj.timeLines;this._xAxisLabels=3Dthis.data.xAxisLabelsObj.ElementList;=
if(this._displayUnit=3D=3D=3D1||this._displayUnit=3D=3D=3D2||this._displa=
yUnit=3D=3D=3D3){this._findOpaqueGridLines();}
this._customDateRange=3Dthis.data.CustomDateRange;try{for(var =
j=3D0;j"+lastPointIcon+"
"
this.targetSelector.append(elm);return;}else{this._drawRoundDot(style,poi=
nt.x,point.y,3);}},_createYAxisLabels:function(type){if(!this.style.maxPr=
iceLines)return;var decimalsToShow=3D2;var YAxisContent=3D"";var =
displayValue=3D"";var x,y,p;var =
elmHeight=3Dthis.style.YAxisLabelHeight;var =
excludeLabel=3D[];if(!this.style.yAxisLabelPadding){this.style.yAxisLabel=
Padding=3D2;}
function =
addCommas(nStr){nStr+=3D'';x=3DnStr.split('.');x1=3Dx[0];x2=3Dx.length>1?=
'.'+x[1]:'';var =
rgx=3D/(\d+)(\d{3})/;while(rgx.test(x1)){x1=3Dx1.replace(rgx,'$1'+','+'$2=
');}
return x1+x2;}
function decimalsNeeded(lineNum,range){var =
Tol=3D5.0e-6;if(range=3D=3D=3D0||lineNum=3D=3D=3D0)
return 0;var maxDecimals=3D6;var division=3Drange/lineNum;var =
decimals=3D0;while(decimals<=3DmaxDecimals){var =
divtest=3Ddivision*Math.pow(10,decimals);if(Math.abs(divtest-Math.round(d=
ivtest))"+addCommas(displayValue)+"
";}else =
if(drawLabel=3D=3D=3Dtrue){YAxisContent=3DYAxisContent+""+addCommas(displayValue)+"
"}}}
catch(e){}
this.targetSelector.append(YAxisContent);},_determineTypeOfChart:function=
(Sessions){if(Sessions.length>=3D1&&Sessions[0].Regions.length>=3D1){var =
numberOfRegions=3DSessions[0].Regions.length;if(numberOfRegions=3D=3D1&&S=
essions[0].Regions[0].Type!=3D4){this._historical=3Dtrue;}
else{this._historical=3Dfalse;}}},_setHLC:function(Sessions){this.lastPoi=
nt.x=3Dnull;this.lastPoint.y=3Dnull;this.lowPoint.x=3Dnull;this.lowPoint.=
y=3Dnull;this.highPoint.x=3Dnull;this.highPoint.y=3Dnull;var =
MinMax=3Dthis._getMinMax(Sessions,false);var =
needsBump=3Dfalse;if(this.data.Data[0].Value.IsIndex=3D=3D=3D1&&this._bar=
Size=3D=3D=3D60){needsBump=3Dtrue;}
if(MinMax.MinPoint!=3Dnull||MinMax.Min!=3Dnull){this.lowPoint=3DMinMax.Mi=
nPoint;}
if(MinMax.MaxPoint!=3Dnull||MinMax.Max!=3Dnull){this.highPoint=3DMinMax.M=
axPoint;}
for(var i=3D0;i